Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

The Preventive Effect of Dexrazoxane and Pentoxifylline on Adriamycin Induced Cardiomyopathy

Dexrazoxane과 Pentoxifylline의 Adriamycin 유발성심근증에 대한 예방 효과

  • Zhu, Ling (Department of Pediatrics Seoul National University College of Medicine) ;
  • Bae, Eun-Jung (Department of Pediatrics Seoul National University College of Medicine) ;
  • Ha, Il-Soo (Department of Pediatrics Seoul National University College of Medicine) ;
  • Seo, Jung-Wook (Department of Pathology Seoul National University College of Medicine) ;
  • Noh, Chung-Il (Department of Pediatrics Seoul National University College of Medicine) ;
  • Choi, Jung-Yun (Department of Pediatrics Seoul National University College of Medicine) ;
  • Yun, Yong-Soo (Department of Pediatrics Seoul National University College of Medicine)
  • 주령 (서울대학교 의과대학 소아과학교실) ;
  • 배은정 (서울대학교 의과대학 소아과학교실) ;
  • 하일수 (서울대학교 의과대학 소아과학교실) ;
  • 서정욱 (서울대학교 의과대학 병리학교실) ;
  • 노정일 (서울대학교 의과대학 소아과학교실) ;
  • 최정연 (서울대학교 의과대학 소아과학교실) ;
  • 윤용수 (서울대학교 의과대학 소아과학교실)
  • Received : 2005.03.11
  • Accepted : 2005.08.03
  • Published : 2005.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : We hypothesized dexrazoxane(DXR) and pentoxifylline(PTX) may prevent myocardial damage in adriamycin(ADR)-induced cardiomyopathic rat model. We also investigated their effects on the myocardial apoptosis and fibrosis in ADR induced cardiomyopathy. Methods : The six-week old female Spregue-Dawley rats were divided into control group(CNT, n=4), ADR group(n=6), ADR+DXR group(DXR, n=5), ADR+PTX group(PTX, n=6), ADR+DXR+PTX group(DXPT, n=5). ADR(5 mg/week, twice) was administrated intravenously to rats except CNT group to induce cardiomyopathy. The PTX(50 mg/kg/day) was administered daily from day-0 to Day-21. The DXR(100 mg/kg) was administered 30 minutes before each ADR injection. On day 21, the rats were sacrificed and the degree of histopathologic changes of hypercontraction band necrosis, cytoplasmic vacuolar change and fibrosis were scored. Immunohistochemical staining for Bcl-2 expression and RT-PCR for $TNF-{\alpha}$ and CTGF were performed. Results : Histopathological scores of myocardial damage were significantly higher in ADR rats than CNT rats(P<0.05), and significantly lower in DXPT rats than ADR rats(P<0.01). Myocardial fibrosis was prevented in both PTX rats and DXPT rats. The expression of Bcl-2 was weaker in ADR rats than that in CNT rats(P<0.05), and stronger in both DXR and DXPT rats than that in ADR rats (P<0.05). $TNF-{\alpha}$ concentration of ADR rats was not different from that of treated groups. Conclusion : DXR prevented myocyte apoptosis with increased Bcl-2 expression, and PTX prevented myocardial fibrosis in ADR induced cardiomyopathic rats. The combination therapy of DXR and PTX showed prevention of cardiomyopathy in ADR induced cardiomyopathy rat model.

목 적 : ADR 유발성심근증 생쥐 모델에서 PTX와 DXR의 심근증에 대한 예방 및 치료 효과를 알아보고자 하였다. 방 법 : 생후 6주된 Sprague-Dawley rat를 정상대조군(n=4), 질환대조군(n=6), DXR군(n=5), PTX군(n=6), 병용치료군(n=5)으로 나누고 정상 대조군을 제외한 4군에 ADR(5 mg/kg)을 1주 간격으로 2회 미정맥으로 투여하여 심근증을 유발하였다. DXR군은 매 ADR 투여 30분 전에 DXR(100 mg/kg)을 미정맥으로 주사하였다. PTX군은 3주간 매일 PTX(50 mg/kg/day)을 경구투여하였다. 5군 모두 3주 뒤에 희생시켜 좌심실 조직의 광학현미경적소견을 관찰하여 심근증의 정도를 분석하였다. 면역조직학적 염색을 통해 Bcl-2 발현의 변화를 조사하였고 $TNF-{\alpha}$와 CTGF에 대한 RT-PCR을 시행하였다. 결 과 : 광학현미경 소견상 세포질의 공포형성과 과수축 밴드괴사 그리고 섬유화는 정상대조군에 비해 질환대조군에서 유의하게 증가하였고 병용치료군에서 감소하였다(P<0.01). 심근 섬유화는 PTX군과 병용치료군에서 ADR군에 비해 유의하게 감소하였다. Bcl-2의 발현은 질환대조군에서 낮았으며 DXR군과 병용치료군에서 질환대조군에 비해 Bcl-2의 발현이 증가하여 호전되었다(P<0.05). $TNF-{\alpha}$는 mRNA와 단백질의 발현상 정상대조군과 질환대조군에서 차이가 없었다. 결 론 : ADR 유발성심근증에 DXR과 PTX를 함께 투여하였을 경우 DXR은 bcl-2의 발현을 증가시키고 심근세포의 자멸사를 억제하였고 PTX는 심근 섬유화를 억제하였다. 그리고 ADR과 PTX를 병용 투여하였을 경우 최대의 심근증 예방 효과를 볼 수 있었다.

Keywords

References

  1. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25(4 Suppl):72S-85S
  2. Robert TD. Cytoprotective agents for antracyclines. Semin Oncol 1996;23:23-34
  3. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, Chadwick DP, et al. The use of serum levels of cardiac troponin T to compare the protective activity of Dexrazoxane against doxorubicin and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001;48:297-304 https://doi.org/10.1007/s002800100348
  4. Della TP, Mazue G, Podesta A, Moneta D, Sammartini U, Imondi AR. Protection against doxorubicin-induced cardiotoxicity in weanling rats by Dexrazoxane. Cancer Chemother Pharmacol 1999;43:151-6 https://doi.org/10.1007/s002800050876
  5. Heon S, Bernier M, Servant N, Dostanic S, Wang C, Kirby GM, et al. Dexrazoxanedoes not protect against Doxorubicin- induced damage in the young rat. Am J Physiol Heart Circ Physiol 2003;285:499-506 https://doi.org/10.1152/ajpheart.00047.2003
  6. Dousa TP. Cyclic 3', 5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 1999;55:29-62 https://doi.org/10.1046/j.1523-1755.1999.00233.x
  7. Takehana H, Inomata T, Niwano H, Nishii M, Matsuda C, Kohno K, et al. Immunomodulatory effect of pentoxifilline in suppressing experimental autoimmune myocarditis. Circ J 2002;66:499-504 https://doi.org/10.1253/circj.66.499
  8. Us MH, Ozkan S, Ogus T, Acar HV, Ege T, Cakir O, et al. Efficacy of topically applied glutamate-aspartate and solutions in decreasing myocardial damage during openheart surgery in rats. J Int Med Res 2001;29:497-502 https://doi.org/10.1177/147323000102900605
  9. Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G, et al. Effects of pentoxifilline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002;90:1118- 22 https://doi.org/10.1016/S0002-9149(02)02779-0
  10. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-$\beta$ in cardiac fibroblasts and cardiac myocytes : a potential role in heart fibrosis. J Mol Cell cardiol 2000;32:1805-19 https://doi.org/10.1006/jmcc.2000.1215
  11. Chana JS, Wilson GD, Cree IA, Alexander RA, Myatt N, Neale M, et al. C-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol 1999; 83:110-4 https://doi.org/10.1136/bjo.83.1.110
  12. Stadelmann C, Lassmann H. Detection of apoptosis in tissue sections. Cell Tissue Res 2000;301:19-31
  13. Park CS, Youn HJ, Cho EJ, Oh YS, Baek SH, Lee JH, et al. Cardioprotective effect of IGF-1 in mouse with ADR induced cardiomyopathy. Korean Circulation J 2002;32:1116- 23 https://doi.org/10.4070/kcj.2002.32.12.1116
  14. Gluck B, Schmidtke M, Merkle I, Stelzner A, Gemsa D. Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. J Mol Cell Cardiol 200133:1615-26 https://doi.org/10.1006/jmcc.2001.1416
  15. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-6 https://doi.org/10.1136/hrt.72.6.561
  16. Usta Y, Ismailoglu UB, Bakkaloglu A, Orhan D, Besbas N, Sahin-Erdemli I, et al. Effects of PTX in ADR-induced renal disease in rats. Pediatr Nephrol 2004;19:840-3
  17. Mohamed HE, Asker ME, Ali SI, El-Fattah TM. Protection against doxorubicin cardiomyopathy in rats : role of phosphodiesterase inhibitors type 4. J Pharm Pharmacol 2004; 56:757-68 https://doi.org/10.1211/0022357023565
  18. Lou H, Danelisen I, Singal PK. Cytokines are not upregulated in ADR-induced cardiomyopathy and heart failure. J Mol Cell Cardiol 2004;36:683-90 https://doi.org/10.1016/j.yjmcc.2004.03.004
  19. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor-$\beta$ in human disease. N Engl J Med 2000;342:1350-58 https://doi.org/10.1056/NEJM200005043421807